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S tudies with either general population or clinical samples show conclusively that individuals with SUDs have a significantly higher prevalence of comorbid mental disorders than those with no SUDs. 1 Nevertheless, the detection of comorbidities declines markedly in natural practice, and they are often not integrated in a treatment plan. 2 Since untreated comorbid mental disorders negatively affect treatment outcome, universal screening for mental disorders among those seeking treatment for substance use disorders is a recommended best-practice guideline. 3 From a cost-benefit perspective, and considering that treatment resources are limited, universal screening for mental disorders among all patients seeking treatment of SUDs can be a better strategy than a routine psychiatric assessment, considering that about one-third or more have no other mental disorders beyond SUDs. 4 Those who screen positive could then be managed accordingly.
The PDSQ, a self-report instrument, was designed to screen for DSM-IV Axis 1 conditions, which are common among patients with SUDs. However, data on its accuracy come only from validation studies with psychiatric outpatients. 5 The validity of any screening instrument varies with the different samples and different circumstances in which it is used, 6 a case in point being the differing mandates and populations across the disparate mental health and addictions treatment systems. Differences in the comorbidities and the severity of the illnesses may also affect the psychometric properties of a screening tool. 7 More specifically, positive and negative predictive values will vary according to the prevalence of the specific disorders to be screened with the PDSQ, and these prevalences are different in an outpatient psychiatric population, compared with a population in treatment for SUDs.
We conducted a study on the validation of the PDSQ among patients in treatment for SUDs to gather preliminary data on its accuracy and better ascertain the need for a larger trial to examine its psychometric properties among those patients. The SCID was considered the gold standard. 8 Our hypothesis was that the psychometric properties of the PDSQ in a population with SUDs would differ, in a clinically meaningful way, from the psychometric properties obtained in a population of psychiatric outpatients as described in the original report by the authors of the PDSQ. 9
Method
We assessed a total of 80 outpatients who received treatment for SUDs from 2 separate sites with the PDSQ, followed by the SCID on the same day. The sequence of instruments was chosen to avoid prompting responses on the PDSQ. The SCID interviewers were blind to the results of the PDSQ. The sites were the Centre for Addiction and Mental Health and the Toronto Western Hospital, both tertiary care teaching hospitals in downtown Toronto, Ontario. Each site provided data on 40 patients.
This was a convenience sample of men and women who were consecutive patients presenting for treatment of SUDs other than those related to nicotine or caffeine, aged 18 to 65 years, and proficient in English. After the project had been fully explained to them, written informed consent was obtained from all patients. The research ethics boards of both sites reviewed and approved the project.
As the PDSQ has a fixed number of questions for each of the diagnoses covered, the possible cut-off scores ranged from 1 to the maximum number of questions for any given diagnosis. Sensitivity, specificity, PPV, and NPV were calculated for each diagnosis across the range of the possible cut-off scores. ROC curve analysis was used to evaluate the PDSQ's diagnostic performance. The AUC was determined as a summary of the test's accuracy. 10 The ROC is a plot of sensitivity by 1-specificity across all possible PDSQ cut-offs, and the AUC is a summary measure of the accuracy of the test that does not depend on the prevalence of the disease, since neither sensitivity nor specificity varies with prevalence. The AUC can be interpreted as the probability that a randomly selected diseased individual has a test result that indicates greater suspicion than would a randomly chosen nondiseased individual's result. 10 The ideal screening measure would have an AUC of 1.0, whereas a random guess would provide an AUC of 0.5. 11 AUCs between 0.5 and 0.7 reflect low accuracy; between 0.7 and 0.9, moderate accuracy; and between 0.9 and 1.0 high accuracy. 7 The Canadian Journal of Psychiatry, Vol 52, No 
Results
Four patients did not complete all modules of the PDSQ and were excluded from the analysis. Of the remaining 76 patients, 39 (51.3%) were women, 10 (13.2%) were living with partners, 25 (32.9%) were separated, 38 (50.0%) were single, and the mean age was 40.6 years (SD 7.1). The mean years of education were 13.8 (SD 2.9), and 71 patients (93.4%) reported English as their primary language. There were no significant differences between the 2 sites.
According to the current DSM-IV diagnoses, the SCID results indicated MDD in 27 patients (35.5%), PTSD in 18 (23.7%), PD in 15 (19.7%), SP in 11 (14.5%), BN in 9 (11.8%), OCD in 5 (6.6%), generalized anxiety disorder in 4 (5.3%), and agoraphobia in 3 (3.9%). Although the PDSQ allows for the diagnosis of somatoform disorder, hypochondriasis, and psychosis, no patient scored positive for them; therefore, these disorders were not included in the analysis.
Sensitivity can be understood as a measure of the screener's ability to correctly identify individuals with a particular disorder. Specificity can be understood as the screener's ability to correctly identify individuals without the disorder. Both sensitivity and specificity do not depend on the prevalence of the disorder. The PPV is the probability that, given a positive screening, a person has a particular disorder. The NPV is the probability that, given a negative screening, a person does not have the disorder. Both the PPV and NPV depend on the prevalence of the disorder. 7 All these parameters vary significantly according to the cut-off point; therefore, the choice of a cut-off score is of utmost importance for a screening test since it will determine the "caseness," with all the implications that entails (treatment, further assessment, referral, and so forth). The choice of a given cut-off score should be informed by the sensitivity, specificity, PPV, and NPV for each possible cut-off.
On assessing the performance of the PDSQ, Table 1 shows the sensitivity, specificity, and the positive and negative predictive values of the PDSQ for all the possible cut-off scores. indicated. As expected, when the cut-off increases, the sensitivity and PPV decrease while the specificity and NPV increase.
The ROC curves were calculated for MDD, PTSD, and PD. The AUCs were 0.86 (95%CI, 0.77 to 0.95; P < 0.001), 0.79 (95%CI, 0.68 to 0.90; P < 0.001), and 0.66 (95%CI, 0.51 to 0.82; P = 0.05), respectively. ROC curves for the other disorders were not computed because of sample size constraints.
Discussion
The cut-off scores for the PDSQ that are suggested in the test manual are targeted toward a sensitivity range of around 90%, except for psychosis, for which the sensitivity is 75%. In our sample, using the same cut-offs resulted in a mean sensitivity of 73%, a mean specificity of 61%, a mean PPV of 27%, and a mean NPV of 96%. Those figures are considerably different from those reported for the PDSQ, which were obtained from a sample of psychiatric outpatients. 12 For MDD, the differences in sensitivity and specificity were negligible, with an increase of 6% in sensitivity and no changes in specificity; PPV decreased 12% and NPV increased 13%. For PTSD, sensitivity declined 3% and specificity dropped 12%; PPV increased 14% and NPV decreased 5%.
For SP, sensitivity was 100%, an increase of 9% over the original value, and specificity decreased 20%, PPV decreased 25%, and NPV increased 5% and reached 100%. For BN, sensitivity declined 21%, specificity decreased 1%, PPV increased from 25% to 43%, and NPV decreased from 99% to 95%.
Since PTSD, BN, and PD were more prevalent in our sample when compared with the disorders that were more common in the original sample from a mental health service, this discrepancy could account for the differences in PPV and NPV.
Our results indicated that AUCs for MDD and PTSD were within the moderate accuracy range, whereas the AUC for PD was in the low accuracy range. In comparison with the AUCs of the original validation sample, the value for MDD was the same, for PTSD it declined from 0.84 to 0.79, and for PD it decreased from 0.89 to 0.66. The latter was only marginally significant as the CI almost included 0.5. For the remaining disorders, ROCs were not calculated because the sample size was too small.
The differences in the AUCs can be attributed to different case mixes in the samples; that is, the prevalence of comorbidities of the disorders is different in a psychiatric outpatient sample compared with a sample, of individuals with SUDs, and those different combinations of disorders can affect the test's ability to detect the disorders being screened. 4, 13 Differences in the severity spectrum for each disorder can also influence accuracy. For instance, if the severity spectrum presents a bimodal distribution; that is, if the affected individuals have a severe form of illness and the nonaffected individuals do not present any signs or symptoms that could be detected by the diagnostic instrument, then sensitivity and specificity will increase. In individuals with SUDs comorbid with other psychiatric disorders, the latter tend to be more severe than in individuals without SUDs. 14, 15 This tendency is another possible explanation for the differences we observed.
Conclusions
The PDSQ is a promising tool to screen for other psychiatric disorders in clinical populations with SUDs, but it should not be used in that population until larger validation studies provide data on its psychometric properties and inform the choice of cut-off scores.
As a preliminary study with a small sample, our study does not have the power to provide information on the PDSQ's accuracy on disorders of low prevalence. A project is currently being initiated to test the PDSQ in larger samples and compare it with other screening tools.
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Résumé : Dépistage des problèmes de santé mentale chez les patients souffrant de troubles liés à l'utilisation d'une substance : résultats préliminaires de la validation d'un instrument d'autoévaluation
Objectifs : Nous avons mené une étude préliminaire sur la validation du questionnaire de dépistage d'un diagnostic psychiatrique (PDSQ) chez les patients suivant un traitement pour les troubles liés à l'utilisation d'une substance (TUS).
Méthode : Nous avons évalué 76 patients souffrant de TUS à l'aide du PDSQ, suivi de l'entrevue clinique structurée pour le DSM-IV. La sensibilité, la spécificité, les valeurs prédictives positives et négatives, et les courbes caractéristiques de fonctionnement du récepteur (ROC) ont été calculées.
Résultats : En général, les propriétés psychométriques identifiées par le PDSQ chez les patients souffrant de TUS différaient de celles découvertes chez les populations psychiatriques ambulatoires. Les courbes ROC ont été calculées pour le trouble dépressif majeur, le trouble de stress post-traumatique et le trouble de panique. Les surfaces sous la courbe étaient 0,86 (95 % IC 0,77 à 0,95, P < 0,001), 0,79 (95 % IC 0,68 à 0,90, P < 0,001), et 0,66 (95 % IC 0,51 à 0,82, P = 0,05), respectivement.
Conclusion : L'utilisation du PDSQ pour dépister d'autres troubles psychiatriques chez les populations souffrant de TUS est prometteuse et exige des études de validation plus vastes afin de fournir des données sur ses propriétés psychométriques et d'éclairer le choix des scores d'inclusion pour cette population.
